|Year : 2020 | Volume
| Issue : 2 | Page : 49
Coronavirus disease-2019 (COVID-19) and its effect on diabetes
Department of Diabetology, Madras Diabetes Research Foundation & Dr. Mohan’s Diabetes Specialities Centre, Chennai, Tamil Nadu, India
|Date of Submission||26-May-2020|
|Date of Acceptance||28-May-2020|
|Date of Web Publication||24-Jun-2020|
Dr. Viswanathan Mohan
Department of Diabetology, Dr. Mohan’s Diabetes Specialities Centre, President & Chief of Diabetes Research, Madras Diabetes Research Foundation, IDF Centre of Excellence in Diabetes Care & ICMR Centre for Advanced Research on Diabetes No 4, Conran Smith Road, Gopalapuram, Chennai 600086, Tamil Nadu.
Source of Support: None, Conflict of Interest: None
|How to cite this article:|
Mohan V. Coronavirus disease-2019 (COVID-19) and its effect on diabetes. J Diabetol 2020;11:49
The pandemic of coronavirus disease (COVID-19) has been one of the greatest medical disasters in recent human history. It has uprooted the lives of many people, infected millions of people all over the world, and resulted in hundreds of thousands of deaths. One of the worrisome facts about COVID-19 is that it disproportionately affects older people and those with uncontrolled diabetes, hypertension, and cardiovascular disease. In this issue of the Journal of Diabetology, we have a series of five articles dealing with COVID-19. In the first article, Unnikrishnan et al. discuss the connection between diabetes and COVID-19 and talk about the precautions that people with diabetes should take.
In the second article, Chopra et al. discuss the link between hypertension and cardiovascular disease and COVID-19. The issue of angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blocker (ARBs) in the context of COVID-19 which became a contentious issue is also discussed. The third article by Anjana et al. discusses the role of hydroxychloroquine (HCQ) which suddenly shot into its prominence after it was shown that it may have a role in the treatment of COVID-19 but later it became a hotly debated issue. The fourth article deals with Vitamin D and COVID-19 which is another contentious issue and this is described in detail by Suvarna and Mohan In the fifth article by Poongothai et al., the problems with conducting clinical trials during COVID-19 are discussed. These series of five articles form a very important contribution to the Journal of Diabetology.
COVID-19 has taught us many new things about the way we practice medicine. The emergence of telemedicine in treating diabetes and the virtual diabetes clinic are other offshoots of COVID-19., These will be discussed in subsequent issues of Journal of Diabetology.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Hussain A, Bhowmik B, do Vale Moreira NC. COVID-19 and diabetes: Knowledge in progress. Diabetes Res Clin Pract 2020;162:108142.
Unnikrishnan R, Saboo B, Kesavadev J, Deshpande D, Aravind SR, Joshi S, et al
. Diabetes and COVID-19. J Diabetol2020.
Chopra HK, Kasliwal RR, Muruganathan A, Wali M, Ram VS. COVID-19 and hypertension & cardiovascular disease. J Diabetol 2020.
Anjana RM, Sastry NG, Ramuu M, Gupta PK, Shalini J, Srivastava BK, et al
. The role of hydroxychloroquine in COVID-19: Where do we stand? J Diabetol 2020.
Suvarna V, Mohan V. Vitamin D and its role in COVID-19. J Diabetol 2020.
Poongothai S, Anjana RM, Aarthy R, Ramesh J, Kastuhuri, Begum MA, et al
. Strategies adopted in conduct of clinical trials amidst COVID-19. J Diabetol 2020.
Board of Governors. Telemedicine Practice Guidelines. In: Supersession of the Medical Council of India; March 25,2020. Available from: https://www.mohfw.gov.in/pdf/Telemedicine.pdf. [Last accessed on 2020 May 18].
Mohan V. COVID-19 and diabetes: A view from India. J Diabetes Sci Technol May 12,2020. [Epub ahead of print]